A Study Evaluating APG777 in Atopic Dermatitis (NCT06395948)
A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis
🩺 Plain-English Summary (8th-Grade Level)
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.
Who can join: Review the eligibility criteria below.
Location: Investigational Site — Fountain Valley, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (94 Sites)
Showing the first 25 of 94 sites.
- Investigational Site — Fountain Valley, California
- Investigational Site — Los Angeles, California
- Investigational Site — San Diego, California
- Investigational Site — New Haven, Connecticut
- Investigational Site — Coral Gables, Florida
- Investigational Site — Jacksonville, Florida
- Investigational Site — Margate, Florida
- Investigational Site — Douglasville, Georgia
- Investigational Site — Chicago, Illinois
- Investigational Site — Skokie, Illinois
- Investigational Site — West Lafayette, Indiana
- Investigational Site — Bowling Green, Kentucky
- Investigational Site — Rockville, Maryland
- Investigational Site — Detroit, Michigan
- Investigational Site — Troy, Michigan
- Investigational Site — Portsmouth, New Hampshire
- Investigational Site — New York, New York
- Investigational Site — Wilmington, North Carolina
- Investigational Site — Boardman, Ohio
- Investigational Site — Mason, Ohio
- Investigational Site — Portland, Oregon
- Investigational Site — Pittsburgh, Pennsylvania
- Investigational Site — Charleston, South Carolina
- Investigational Site — Nashville, Tennessee
- Investigational Site — Dallas, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.